A yeast-based screen reveals that sulfasalazine inhibits tetrahydrobiopterin biosynthesis by Chidley, Christopher et al.
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Most small-molecule drugs elicit their therapeutic activity by interfering with the function of one or more proteins by physically binding to them. The identification of all 
protein targets of a drug therefore provides the basis for the under-
standing of its beneficial or deleterious actions. However, the iden-
tification of drug-protein interactions remains a challenging task, as 
testified to by the fact that the primary targets of various clinically 
approved drugs remain unknown. Numerous strategies have been 
developed to directly or indirectly identify the targets of bioactive 
small molecules1,2. The most popular approach to directly identify 
drug-protein interactions relies on affinity chromatography using an 
immobilized drug. Chemical proteomics, which associates affinity 
chromatography with mass spectrometry detection, is widely used 
for drug profiling3. Despite various technical advances3, the use 
of chemical proteomics nevertheless remains difficult for identi-
fication of low-abundance target proteins or proteins with low 
solubility or stability in cell extracts. There is therefore a generally 
acknowledged need for alternative approaches to identify drug- 
protein interactions.
Here we describe an approach for drug profiling combining 
an improved yeast three-hybrid (Y3H) system for identification 
of drug-protein interactions with affinity chromatography for 
 unambiguous validation of binding. We applied the approach to the 
profiling of clinically approved drugs, resulting in identification of 
known and unknown drug-protein interactions.
RESULTS
A Y3H system based on SNAP-tag labeling
The Y3H system is a modified version of the yeast two-hybrid 
(Y2H) system adapted for detection of drug-protein interactions. It 
requires derivatization of the drug of interest with a ligand that can 
be anchored to a DNA-binding protein inside yeast cells; the inter-
action of the anchored drug with a target protein is then detected 
by linking their association to the transcriptional activation of a 
reporter gene4. Attractive features of this drug profiling approach 
include (i) the availability of diverse cDNA libraries from different 
tissues and organisms, (ii) the possibility of directly identifying the 
drug-binding domains of proteins, (iii) the possibility of  detecting 
low-abundance proteins and (iv) its experimental simplicity. 
However, although promising initial results have been obtained4,5, 
the Y3H system has scarcely been used for drug profiling. Possible 
reasons for this scarce use include (i) the need to couple the drug of 
interest to a specific ligand, (ii) the low uptake of synthetic mole-
cules into yeast and the associated low sensitivity of the Y3H sys-
tem, as well as (iii) the large number of false positives coming out of 
screenings and the ensuing difficulty in identifying true interactions 
amongst false positives.
We based our Y3H system on the covalent labeling of SNAP-tag 
fusion proteins inside yeast cells by O6-benzylguanine (BG) deriva-
tives6 (Fig. 1a). BG derivatives can be directly coupled to a variety 
of functional groups, facilitating the required derivatization of the 
drug (Supplementary Methods). To establish SNAP-tag–based 
Y3H screening as a robust and easy-to-use tool for drug profiling, 
we first developed and characterized a system that addresses the 
shortcomings of previous strategies.
Development of a sensitive SNAP-tag–based Y3H system
The extent of SNAP-tag labeling with the drug of interest depends 
on the intracellular concentration of the drug derivative. We 
hypothesized that an increase in such intracellular concentration 
would yield a corresponding increase in sensitivity of the SNAP-
tag–based Y3H system. The intracellular accumulation of drugs 
in Saccharomyces cerevisiae is frequently hindered by an efficient 
multidrug-resistance mechanism. Yeast cells express a variety of 
ATP-binding cassette transporters that confer drug resistance when 
overexpressed or hypersensitivity when deleted. We therefore deleted 
three genes (PDR5, SNQ2 and YOR1) encoding broad-spectrum 
drug transporters from the genome of a commercially available Y3H 
reporter yeast strain (Supplementary Results and Supplementary 
Methods). Indeed, it has been shown that triple deletion of PDR5, 
SNQ2 and YOR1 increases the sensitivity of yeast to an extremely 
broad range of compounds7; furthermore, the labeling of SNAP-tag 
fusion proteins in yeast cells with fluorescent BG derivatives is effi-
cient in a yeast strain with the same three deletions8. We quantified 
SNAP-tag labeling in the triple deletion reporter strain (1A2) and 
compared it to that of the unmodified reporter strain (NMY51). 
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We observed that triple deletion of PDR5, SNQ2 and YOR1 increases 
the labeling efficiency of different BG drug derivatives up to four-
fold (Supplementary Fig. 2a–d).
In order to characterize the sensitivity of our Y3H system in the 
1A2 strain, we performed model studies based on the binding of 
methotrexate to E. coli dihydrofolate reductase (eDHFR). We chose 
this interaction because it has been shown that derivatization of 
methotrexate at its glutamyl γ-carboxyl group does not affect bind-
ing to eDHFR9 and that a BG derivative of methotrexate (BG-Mtx) 
dimerizes SNAP-tag and eDHFR in yeast10. Furthermore, the bind-
ing strength of methotrexate to eDHFR can be modulated by single 
point mutations. In addition to wild-type eDHFR, we prepared 
three mutants that cover a wide range of binding affinities (KD from 
20 pM to 9 μM)11,12. We then tested the Y3H growth induced by 
 coexpression of SNAP-tag and eDHFR fusion proteins at differ-
ent concentrations of BG-Mtx (Fig. 1b). We were able to detect 
the interaction of methotrexate with eDHFRF31V,L54G (KD = 9 μM), 
indicating that the sensitivity of the SNAP-tag–based Y3H system 
presented here is in the low micromolar range. We next compared 
the performance of 1A2 to that of NMY51 and observed that the 
deletion of PDR5, SNQ2 and YOR1 increases significantly the sensi-
tivity of the SNAP-tag–based Y3H system (Supplementary Fig. 3).
Elimination of false positives
The use of cDNA libraries in Y2H and Y3H screenings often results 
in the isolation of false positives, mainly due to the presence of hybrid 
proteins expressed in the wrong reading frame or from untranslated 
regions of mRNA13. Methods have been developed that minimize 
the occurrence of false positives either by increasing the stringency 
of the system or by providing efficient ways of combing out non-
specific interactions14; however, such increase in stringency is often 
at the expense of sensitivity. In the SNAP-tag–based Y3H system, 
we use two successive strategies for false positive elimination.
In a first step, the number of false positive colonies inherent 
to cDNA library screenings can be reduced by negative selection 
against unspecific interactions in the absence of drug derivative. 
Specifically, the anti-metabolite 5-fluoroorotic acid (5-FOA) can be 
used to select against unspecific interactions that activate the URA3 
reporter gene in the 1A2 strain in the absence of drug derivative, 
as the product of the URA3 gene transforms 5-FOA into a toxic 
compound (Supplementary Fig. 4a–c). We tested the efficacy of 
such a negative selection round in model screenings and observed 
a reduction in the number of unspecific interactions by a factor of 
30 to 70, suggesting that a negative selection step should effectively 
lower the number of false positive colonies in cDNA library screen-
ings (Supplementary Fig. 5a–c).
In a second step, false positives arising after positive selection 
can be eliminated in a simple respotting assay in which yeast growth 
is measured both in the presence and absence of the drug deriva-
tive, as only the growth of yeast cells containing true interactions is 
dependent on the presence of the drug derivative (Fig. 2a).
Verification of interactions
The verification of interactions is a difficult task in Y2H and Y3H 
screenings. To address this bottleneck, we established a strategy for 
an effective pulldown assay that utilizes the same BG drug derivative 
as used in the Y3H screenings (Fig. 2b). Specifically, the BG drug 
derivative is coupled to a glutathione S-transferase (GST)-SNAP 
fusion protein and the target protein transiently expressed with an 
epitope tag in mammalian cells. Pulldowns using glutathione beads 
in the presence and absence of underivatized drug and subsequent 
detection of the epitope-tagged protein through western blotting 
permit a rapid validation of the binding of the underivatized drug 
to the target protein. Furthermore, the same BG drug derivatives 
can be used to validate interactions by affinity chromatography of 
endogenous proteins.
Profiling of clinically approved drugs
Clinically approved drugs covering different therapeutic areas were 
subjected to our Y3H screening system after being derivatized with 
BG (Table 1 and Supplementary Fig. 6a). These approved drugs 
include extensively profiled drugs, such as the kinase inhibitors 
dasatinib and erlotinib, and drugs with obscure mechanisms of 
action, such as the anti-inflammatory agent sulfasalazine. Although 
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Figure 1 | A Y3H system based on SNAP-tag labeling. (a) Illustration of the SnAP-tag–based Y3H system developed for identification of drug-protein 
interactions. A BG derivative of the drug of interest (D) covalently labels SnAP-tag in living yeast cells. The interaction of the covalently anchored drug 
with a target protein (X) is detected by linking their association to the transcriptional activation of a reporter gene. (b) Characterization of the sensitivity 
of the system by analysis of the Y3H growth induced by drug-protein interactions of defined affinity. The binding of methotrexate (Mtx) to E. coli DHFR 
(eDHFR) can be modified by the introduction of point mutations to cover a wide range of binding affinities. The mentioned binding affinities are published 
values for the binding of underivatized methotrexate to eDHFR or to an eDHFR mutant11,12. Yeast cells coexpressing lexA-SnAP and GAl4AD-eDHFR 
(or GAl4AD-eDHFR mutant) were spotted on growth medium selective for reporter gene activation at different concentrations of a BG-methotrexate 
derivative (BG-Mtx). Scale bar, 5 mm.
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in some cases (atorvastatin, erlotinib and indomethacin) the deriva-
tization was expected to interfere with the binding to the drug’s 
primary target, we used these derivatives to search for additional 
targets. It should be noted that for target deconvolution purposes 
it is important to test the BG derivatives in an appropriate assay to 
ensure that activity is retained or to prepare derivatives modified at 
different positions. We also included two negative controls in the 
Y3H screenings, BG and BG-(PEG)4, that label SNAP-tag with a 
benzyl group and with a benzyl-polyethylene glycol (PEG) linker 
respectively. All BG drug derivatives and the two negative controls 
efficiently labeled SNAP-tag in vitro (Supplementary Fig. 6b).
Various cDNA libraries prepared from human tissue are 
commer cially available. However, certain proteins can be under-
represented in tissue-specific libraries13. To minimize the occur-
rence of underrepresented proteins, we transformed human cDNA 
 libraries from diverse tissues in yeast strain 1A2 in preparation for 
Y3H  screenings. Furthermore, we reduced the rate of false positives 
from certain cDNA libraries by performing a negative selection with 
5-FOA before positive selection (Supplementary Fig. 7a,b).
We screened each drug derivative and the two controls against 
eight human cDNA library preparations for a total of 80 Y3H 
screens; 3,069 colonies grew on the selection plates and 849 of these 
showed growth dependence on the presence of the drug derivative 
(Supplementary Fig. 7c,d). The two negative controls did not yield 
a single colony that showed compound growth dependence in any of 
the eight libraries. This demonstrates that our SNAP-tag–based Y3H 
screenings generate few false positives (Supplementary Fig. 8a,b). 
We sequenced the cDNA library insert of all 849 Y3H hits and 
determined a total of 33 drug-protein interactions that were each 
represented between 1 and 237 times (Table 1 and Supplementary 
Fig. 8c,d). The following sections discuss the obtained results.
methotrexate
Methotrexate is an antineoplastic antimetabolite with immuno-
suppressant properties that acts by potent inhibition of human 
DHFR (hDHFR) (Ki = 5 pM). We used this interaction as a  positive 
control to test the efficacy of the SNAP-tag–based Y3H system. 
We identified a total of 173 hits dependent on the presence of the 
methotrexate derivative for growth; all 173 hits encoded hDHFR or 
a fragment thereof, demonstrating the efficacy of our Y3H system. 
Unexpectedly, we observed that no cDNA insert contained hDHFR 
in frame with GAL4AD (Supplementary Fig. 9a). Although it has 
been shown by others that out-of-frame fusion proteins can be 
detected in Y2H screenings15, we analyzed the efficiency of trans-
lational frameshifting in the SNAP-tag–based Y3H system by 
testing the ability of both hDHFR and eDHFR fused in all three 
possible reading frames to GAL4AD to activate transcription of the 
reporter gene in a methotrexate-DHFR Y3H growth assay. All con-
structs (except eDHFR in the +1 reading frame) showed a similar 
performance in the Y3H growth assay (Supplementary Fig. 9b). 
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Figure 2 | Illustration of the yeast-based platform for drug profiling. (a) The SnAP-tag–based Y3H system allows the screening of human cDnA libraries 
for identification of the target(s) of small-molecule drugs (D). Yeast cells coexpressing lexA-SnAP and GAl4AD-X (X: cDnA library clone) are spread on 
growth medium selective for reporter gene activation and in the presence of a BG derivative of the drug of interest (BG-D). Specific Y3H hits are identified 
by testing all colonies growing on the selection plates for dependence on the presence of BG-D for growth on selective medium. The identities of the Y3H 
hits are determined by sequencing of the cDnA inserts and subsequent BlAST analysis. (b) Independent validation of the binding of the drug of interest 
to a target protein by affinity chromatography using the same drug derivative. A drug affinity matrix is prepared by immobilization of a GST-SnAP fusion 
protein on glutathione beads and subsequent reaction of SnAP-tag with BG-D. An epitope-tagged (*) target protein is overexpressed in mammalian cells. 
The specific binding of the target protein from a cell extract to the immobilized drug can be detected by western blotting. The binding of the underivatized 
drug to the target protein can be identified through competition experiments as shown in the schematic.
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Furthermore, we observed a reduced growth rate of both in-frame 
constructs compared with the out-of-frame constructs on nonselec-
tive plates. This reduced fitness could deplete the in-frame clone 
from the libraries. Taken generally, these results indicate that cDNA 
inserts in all three reading frames can encode true interactors and 
that the toxicity of cDNA inserts could be attenuated by reducing 
the expression level through frameshifts (Supplementary Fig. 9c).
Kinase inhibitors dasatinib, purvalanol b and erlotinib
Dasatinib is an ATP-competitive tyrosine kinase inhibitor used in 
the treatment of chronic myelogenous leukemia. We identified in 
our screenings 16 protein kinases and kinase domains as targets of 
dasatinib (Table 1). Dasatinib has been extensively profiled using a 
variety of methods, including direct binding assays with 287 recom-
binant kinases16. The drug binds to a total of 86 kinases (KD < 10 μM), 
40 with high affinity (KD < 30 nM). All 16 kinases identified in our 
screening have a reported KD for dasatinib below 30 nM. We reasoned 
that only high-affinity interactions were detected in our screening, 
as the drug needs to compete in the cell with  milli molar concentra-
tions of ATP. Having identified 40% of the subset of tight-binding 
kinases, we compared our results with two existing  studies for target 
identification of dasatinib (Supplementary Table 1). One study used 
a quantitative chemical proteomics methodology that analyzes the 
competition between a drug and a mixed kinase- inhibitor affinity 
resin (‘Kinobeads’) by quantitative mass spectrometry17 to identify 
17 of the 40 high-affinity binders. The other study used covalently 
immobilized dasatinib in chemical proteomics experiments to iden-
tify 20 of the 40 high-affinity binders as targets of dasatinib18. Both 
chemical proteomics approaches were more successful in identifying 
weak dasatinib-kinase interactions, presumably due to more favor-
able ratios of derivatized drug to ATP in lysates. Pair-wise compari-
son of the three data sets shows that the two chemical proteomics 
studies share the greatest similarity (Supplementary Table 1). This 
observation reflects the fact that Y3H screening of cDNA libraries 
allowed the identification of fragments encoding the soluble kinase 
domain of several trans membrane receptor tyrosine kinases. Entire 
integral membrane proteins are difficult to identify in both chemi-
cal proteomics experiments and Y3H screenings.
Five of the cDNA libraries used in the dasatinib Y3H screen-
ings provided unique hits (Supplementary Table 2), thus empha-
sizing the importance of using cDNA libraries from different 
tissues. As a significant number of dasatinib hits were out of frame 
(Supplementary Table 2), we believe that the resulting attenuated 
expression level of potentially toxic human cDNA inserts such as 
kinases favors the isolation of out-of-frame inserts.
Finally, we identified an out-of-frame insert encoding hydroxy-
acyl–coenzyme A dehydrogenase (HADH) from four different 
cDNA libraries, but no interaction between HADH and dasatinib 
was detected in validation experiments (Supplementary Fig. 10a,b). 
We speculate that a ternary complex between dasatinib, the in-frame 
peptide and a yeast kinase might be responsible for the selection of 
the out-of-frame HADH insert (Supplementary Fig. 10a–c).
Purvalanol B was developed for inhibition of cyclin-dependent 
kinases (CDKs); however, it also binds to other kinases17. We iso-
lated a number of kinases that have also been identified by others 
(Table 1 and Fig. 3a)5,17. Notably, we identified an indirect inter-
action between purvalanol B and CDK5 and ABL1 enzyme substrate 
1 (CABLES1) in yeast cells. Indeed, immobilized purvalanol B effi-
ciently isolated CABLES1 from a mammalian cell extract but failed 
to isolate it from a bacterial extract (Supplementary Fig. 10d). This 
observation suggests that the Y3H interaction is bridged through a 
yeast protein kinase, such as CDK2 or CDK5, and that Y3H screen-
ings can also capture indirect binders.
Erlotinib is a drug used in the treatment of non–small cell lung 
cancer and pancreatic cancer; it is a reversible ATP-competitive 
inhibitor of epidermal growth factor receptor (EGFR). We 
 derivatized erlotinib at its terminal alkyne moiety even though 
structural information suggested that this should interfere with 
its binding to EGFR and other kinases19. In concordance, we were 
not able to isolate kinases from Y3H selections using this erlotinib 
derivative, but we identified oxysterol-binding protein–related 
protein 7 (ORP7) as the first, to our knowledge, nonkinase target 
of the drug. We confirmed the binding of BG-derivatized 
and underivatized erlotinib to ORP7 using a pulldown assay 
Table 1 | chemical structures of the compounds used in this 
study and the corresponding protein targets identified using 
the yeast-based platform for drug profiling. 
Compounda protein targetb
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HO
N N N
N
HN
S
N
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Dasatinib
LcK (138×) 
HADH (62×)
FYN (38×)c 
FgR (34×)
bTK (6×) 
cSK (5×)
EPHA4 (3×) 
EPHb3 (3×)
TEc (3×)
EPHA2 (2×) 
EPHb2 (2×)
FRK (2×) 
KIT (2×)
EPHb4 (1×) 
AbL2 (1×)
DDR1 (1×) 
mAPK14 (1×)
HO
Cl NH
N
N N
NN
H
OH
O
Purvalanol B
PTK2b (4×)c
FYN (3×)
CABleS1 (2×)c
cLK2 (2×)
EPHA4 (1×)
NH
N
N
O
O
O
O
Erlotinib
oRP7 (17×)c
HO
O OH OH
N
HN
F
O
Atorvastatin
PDE6D (237×)c
NQo2 (29×)c,d
ABR (16×)
AlDH1A2 (2×)
AlDH1A3 (2×)
TBK1 (1×)
CoQ9 (1×)
HO
O
N
HO
N
S
O
O H
N N
Sulfasalazine
SPR (3×)c,d
HO
O
S
O
O
NH2
ClN
H
O
Furosemide
cAII (6×)
HO
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O
O
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Indomethacin
aDrugs were linked to O6-benzylguanine at the functional group highlighted in red. bThe number of 
hits displayed for each protein target represents the total number of independent yeast colonies 
identified during the cDnA library screenings. Protein targets marked in bold are previously known 
targets. cDrug targets validated in this study by affinity chromatography. dDrug targets validated in 
this study in an activity assay.
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(Fig. 3b). In contrast, we observed that neither gefitinib nor 
lapatinib, two other specific EGFR inhibitors, were able to 
bind ORP7 (Fig. 3c). We next prepared a fluorescent deriva-
tive of erlotinib (erlotinib-TMR) and used it in fluorescence 
colocalization experiments. In fixed and permeabilized human 
U2OS cells, we observed colocalization of erlotinib-TMR with 
epitope-tagged ORP7 (Fig. 3d and Supplementary Fig. 11a,b). 
Finally, we analyzed the binding of erlotinib-TMR to recombi-
nant ORP7 in fluorescence polarization experiments (KD = 230 
nM, Supplementary Fig. 11c,d). Furthermore, we observed that 
underi vatized erlotinib efficiently competes for binding to ORP7 
(IC50 = 100 nM, Supplementary Fig. 11e).
ORP7 is one of 12 members of the ORP family. ORPs are associ-
ated with diverse cellular functions such as control of lipid synthesis, 
transport and metabolism, transport of sterols and modulation of 
signal transduction; however, the function of individual ORP family 
members is not well characterized20. ORP7 is an 842-residue protein 
containing a sterol-binding domain at its C-terminal end (440–830). 
Notably, the shortest ORP7 hit isolated in the Y3H screenings com-
prised amino acids 440–842, indicating that the sterol-binding 
domain of ORP7 is involved in the interaction with erlotinib. As 
ORP7 is the first nonkinase target of erlotinib, this interaction and 
its physiological role merit further investigation. In addition, as the 
natural substrate and the physiological role of ORP7 are unknown, 
derivatized erlotinib represents an interesting tool compound.
Atorvastatin
Atorvastatin is a member of the statin drug class that is used for the 
treatment of hypercholesterolemia; it is a competitive  inhibitor of 
3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA reductase). 
The HMG-like moiety of atorvastatin occupies the enzyme’s active 
site, whereas the rigid hydrophobic part of the drug occupies a shal-
low nonpolar groove21. Although derivatization of atorvastatin at its 
carboxyl group interferes with binding to HMG-CoA reductase, we 
speculated that this derivative could allow the identification of off-
targets. In this study, we indeed identified  several off-targets of ator-
vastatin. The most abundant hits identified in the Y3H screenings 
were the delta subunit of retinal rod phosphodiesterase (PDE6D) 
and quinone reductase 2 (NQO2) (Fig. 4a). The interaction of 
atorvastatin with PDE6D and NQO2 has been reported in a patent 
application, although no details are provided as to how these inter-
actions were identified22.
We confirmed the binding of atorvastatin to PDE6D in a pull-
down assay using both epitope-tagged and endogenous protein 
(Fig. 4b and Supplementary Fig. 12a). We then tested the binding 
of eight other statins to PDE6D, finding that only atorvastatin can 
bind PDE6D (Fig. 4c). In addition to its role in the regulation of the 
activity of retinal rod phosphodiesterase, it has been suggested that 
PDE6D plays a broader role in cellular signaling23. PDE6D binds 
protein members of the Ras, Rap, Rho and Rab families by accom-
modation of their prenyl groups in a hydrophobic pocket, in a way 
that is similar to that of guanine nucleotide dissociation inhibitors23. 
We assume that atorvastatin binds to that hydrophobic pocket. 
The interaction of PDE6D with prenylated proteins affects their 
intra cellular localization. As statins inhibit both the biosynthesis 
of choles terol and isoprenoids, they reduce the prenylation of pro-
teins and interfere with their membrane localization24. There is an 
intriguing possibility that atorvastatin is directly affecting protein 
localization through binding to the prenyl-binding site of PDE6D.
NQO2 is a flavoprotein that catalyzes the reduction of quinones 
and is thought to be involved in metabolic reduction and xeno biotic 
detoxification25. It has been shown that imatinib, a drug used in the 
treatment of chronic myelogenous leukemia, binds and inhibits 
NQO2 (half-maximal inhibitory concentration (IC50) = 80 nM)25. 
Here, we found that atorvastatin binds to NQO2 and inhibits the 
activity of NQO2, albeit with much weaker potency (IC50 ~ 50 μM) 
than imatinib (Fig. 4d and Supplementary Fig. 12b). The relatively 
high IC50 of atorvastatin for NQO2 raises the question whether this 
interaction is of physiological relevance.
Finally, we isolated hits encoding the GTPase-activating domain 
of active breakpoint cluster region–related protein (Abr), two 
members of the retinaldehyde dehydrogenase family (ALDH1A2 
and ALDH1A3), ubiquinone biosynthesis protein COQ9, and a 
C-terminal fragment of TANK-binding kinase 1 (TBK1). Although 
we confirmed these Y3H hits in retransformed yeast cells (Fig. 4a), the 
interaction of atorvastatin with these proteins could not be validated 
in pulldown assays (Supplementary Fig. 12c,d). Further experi ments 
are needed to evaluate the significance of these findings.
Sulfasalazine
Sulfasalazine is an anti-inflammatory drug used against inflam-
matory bowel diseases (IBDs) such as ulcerative colitis, as well as 
against rheumatoid arthritis. Despite its medical importance, the 
mechanism of action of sulfasalazine remains obscure. Sulfasalazine 
is incompletely absorbed from the small intestine and carried to the 
colon where it is reduced by bacteria to sulfapyridine and mesala-
mine26. The therapeutic effect of sulfasalazine in IBDs results, at least 
partially, from the topical release of mesalamine in the colon. It has 
been suggested that the anti-inflammatory activity of  mesalamine is 
because of its binding to peroxisome proliferator-activated receptor-γ 
(PPAR-γ)27. Sulfasalazine and mesalamine, however,  differ in their 
therapeutic properties in IBDs, as sulfasalazine shows  superior 
 efficacy in maintaining remission of ulcerative colitis28. More impor-
tantly, only sulfasalazine shows efficacy against rheumatoid  arthritis. 
The differences between sulfasalazine and mesalamine could be due 
Figure 3 | Analysis of hits obtained from purvalanol b and erlotinib 
profiling. (a) A purvalanol B affinity matrix was prepared by binding 
of GST-SnAP to glutathione beads and reaction of SnAP-tag with BG-
purvalanol B. A lysate of human u2oS cells expressing v5 epitope-tagged 
PTK2B or CABleS1 was incubated with the purvalanol B affinity matrix. 
Protein bound to the affinity matrix was analyzed by immunoblotting with 
a horseradish peroxidase (HRP)–labeled anti-v5 antibody. For competition 
experiments, the lysate was preincubated with underivatized purvalanol  
B (10 μM (+) or 100 μM (++)). (b) An erlotinib affinity matrix was 
prepared by binding of GST-SnAP to glutathione beads and reaction of 
SnAP-tag with BG-erlotinib. A pulldown assay of v5-oRP7 was performed 
in an analogous way to that described above. (c) Analysis of the binding 
of underivatized eGFR inhibitors to oRP7 in a competition pulldown assay. 
A lysate of human u2oS cells expressing v5-oRP7 was preincubated 
with erlotinib, lapatinib or gefitinib (10 μM (+) or 100 μM (++)) before 
performing a pulldown assay as described above. Full blots are available 
in Supplementary Figure 14a. (d) Micrographs showing colocalization 
of a fluorescent erlotinib derivative with epitope-tagged oRP7. Fixed and 
permeabilized human u2oS cells expressing v5-oRP7 were stained with 
a tetramethylrhodamine (TMR) derivative of erlotinib (erlotinib-TMR) and 
with an anti-v5-fluorescein antibody conjugate (anti-v5-FITC). The cells 
were imaged by wide-field fluorescence microscopy. Scale bar, 10 μm.
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to their respective pharmacokinetics; alternatively,  sulfasalazine or 
sulfapyridine could have additional targets29,30.
In the SNAP-tag–based Y3H screenings, we identified the enzyme 
sepiapterin reductase (SPR) as a target of sulfasalazine (Fig. 5a). 
We confirmed the binding of BG-derivatized and underivatized 
sulfasalazine to SPR in a pulldown assay using epitope-tagged and 
endogenous SPR (Fig. 5b,c). SPR catalyzes the NADPH-dependent 
reduction of pyruvoyl-tetrahydropterin to tetrahydrobiopterin 
(BH4), this being the final step in the biosynthesis of the  cofactor 
BH4 (ref. 31). BH4 is used by hydroxylases that are involved in the 
biosynthesis of tyrosine, dopamine and serotonin; it is also used 
by glyceryl ether mono oxygenases that generate lipids that are 
involved in signal transduction. Finally, all nitric oxide synthases 
(NOS) require a tightly bound BH4 for activity. We next studied the 
inhibition of recombinant SPR by sulfasalazine in an activity assay 
(Supplementary Methods), finding that underivatized sulfasalazine 
inhibited SPR with an IC50 of 23 nM (Fig. 5d). By comparison, the 
known SPR inhibitor N-acetylserotonin (Ki = 0.12 μM)32 had an IC50 
of 3.1 μM in the same conditions. The principal metabolites of sul-
fasalazine also inhibited SPR although with lower potency: sulfapyri-
dine and N-acetylsulfapyridine inhibited SPR with IC50s of 480 nM 
and 290 nM, respectively, whereas mesalamine inhibited SPR with an 
IC50 of 370 μM (Fig. 5d). In comparison, the reported IC50 value of 
mesalamine for PPAR-γ in a competitive binding assay is 15.2 mM27. 
We next measured the effect of sulfasalazine and its metabolites on 
intracellular, total biopterin levels in a cellular assay (Supplementary 
Methods). At submillimolar concentrations, sulfasalazine, sulfapyri-
dine and N-acetylsulfapyridine effectively reduced intracellular 
biopterin levels, indicating inhibition of BH4 biosynthesis (Fig. 5e). 
Sulfapyridine and N-acetylsulfapyridine show higher activity in the 
cellular assay relative to sulfasalazine, reflecting the fact that sul-
fasalazine is a known substrate of efflux pumps33. Consistent with its 
lower in vitro inhibitory activity, mesalamine affects BH4 biosynthe-
sis at higher concentrations (>1 mM). Overall, the data demonstrate 
that sulfasalazine and its metabolites are inhibitors of SPR in vitro and 
in cell culture. We propose that the inhibition of BH4 biosynthesis by 
sulfasalazine and its metabolites is crucially involved in the mecha-
nism of action of the drug. Our reasoning is based on the demon-
stration that inhibitors of BH4 biosynthesis have been shown to 
reduce the production of nitric oxide (NO) in various inflammatory 
models34,35. Both increased NO levels and increased inducible NOS 
(iNOS) activity have been associated with rheumatoid arthritis36 and 
IBDs respectively37, and selective iNOS inhibitors reduced inflamma-
tion both in rheumatoid arthritis38 and ulcerative colitis39 models.
The concentrations of sulfasalazine and its metabolites required 
for inhibition of BH4 biosynthesis in the cellular assay are within the 
range of their in vivo concentrations. The combined concentration 
of sulfapyridine and N-acetylsulfapyridine in serum and in synovial 
fluid during standard sulfasalazine therapy is around 100 μM40; the 
corresponding values for sulfasalazine and mesalamine are both 
around 15 μM40. Sulfapyridine is likely to be the active component 
of sulfasalazine in rheumatoid arthritis in view of its efficient BH4 
biosynthesis inhibition in cell culture and the concentrations men-
tioned above. Indeed, it has been reported that sulfapyridine alone 
also shows efficacy against rheumatoid arthritis41.
With respect to IBDs, the intraluminal colonic concentration of 
mesalamine during sulfasalazine therapy is around 14 mM, as most 
of sulfasalazine is carried to the colon42. Even higher intraluminal 
colonic concentrations are reached with mesalamine formulations 
for topical delivery43. Given the high intraluminal concentrations 
and the BH4 biosynthesis inhibitory profiles of sulfasalazine and its 
metabolites, it is possible that all contribute to inhibition of BH4 
biosynthesis in the colonic epithelium, thereby complementing 
other mechanisms of action of mesalamine in IBDs.
Furosemide and indomethacin
Furosemide is a diuretic that is used to treat excessive fluid accumu-
lation and body swelling by reducing the reabsorption of electro-
lytes, primarily by inhibition of the Na+-K+-2Cl− symporter. It also 
inhibits members of the carbonic anhydrase family44. We identified 
carbonic anhydrase 2 as a target of furosemide but could not detect 
the Na+-K+-2Cl− symporter in this study because it is an integral 
membrane protein and therefore cannot be expressed functionally 
in the nucleus of yeast cells.
Indomethacin is a nonsteroidal anti-inflammatory drug whose 
effect is primarily attributed to nonselective inhibition of cyclo-
oxygenase 1 (COX-1, Ki = 0.016 μM) and 2 (COX-2, Ki = 5 μM)45. 
The derivatization of indomethacin with BG at its carboxyl group 
should disrupt the interaction with its main targets46. In concordance, 
we were not able to detect these interactions in the Y3H screen-
ings. The results obtained with furosemide and indomethacin illus-
trate two shortcomings and define future challenges of the Y3H 
approach: the inability to detect integral membrane protein targets 
and the need to derivatize the drug of interest.
Figure 4 | Analysis of hits obtained from atorvastatin profiling.  
(a) The binding of atorvastatin to a number of human proteins was 
identified in SnAP-tag–based Y3H screenings and subsequently confirmed 
in retransformed yeast cells. Yeast cells coexpressing lexA-SnAP and 
GAl4AD-X (X = PDe6D, nQo2, ABR, AlDH1A2, AlDH1A3, TBK1 or 
CoQ9) were spotted on selective medium both in the presence and the 
absence of BG-atorvastatin. Scale bar, 5 mm. (b) An atorvastatin affinity 
matrix was prepared by binding of GST-SnAP to glutathione beads and 
reaction of SnAP-tag with BG-atorvastatin. Recombinant PDe6D was 
incubated with the affinity matrix and protein bound to the matrix was 
analyzed by SDS-PAGe and Coomassie staining. (c) The binding of various 
statins to PDe6D was tested in a competition binding assay. Recombinant 
PDe6D (2.5 μM) was preincubated with underivatized statin (100 μM) 
before incubation with the atorvastatin affinity matrix. Protein bound  
to the matrix was analyzed by SDS-PAGe and Coomassie staining.  
The absence of PDe6D bound to the affinity matrix indicates binding of 
the underivatized statin to PDe6D. (d) A lysate of human u2oS cells 
expressing v5 epitope-tagged nQo2 was incubated with the atorvastatin 
affinity matrix. Protein bound to the affinity matrix was analyzed by 
immunoblotting with a HRP-labeled anti-v5 antibody. Full gels and blots 
are available in Supplementary Figure 14b.
a
At
orv
as
tat
in
Ro
su
va
sta
tin
Pra
va
sta
tin
Flu
va
sta
tin
Lo
va
sta
tin
M
ev
as
tat
in
Sim
va
sta
tin
Pit
av
as
tat
in
Ce
riv
as
tat
in
PDE6D
Competitor:
d
+–
In
pu
t
BG-atorvastatin
V5-NQO2
b
+–
In
pu
t
BG-atorvastatin
PDE6D
c
ABR
PDE6D
ALDH1A3
ALDH1A2
NQO2
COQ9
TBK1
Control
Nonselective
medium
Selective
medium
Selective +
BG-atorvastatin
Serial dilutions
©
 2
01
1 
N
at
u
re
 A
m
er
ic
a,
 In
c.
  A
ll 
ri
g
h
ts
 r
es
er
ve
d
.
nature CHeMICaL BIOLOGY | vol 7 | june 2011 | www.nature.com/naturechemicalbiology 381
articleNATURE cHEmIcAL bIoLogY dOI: 10.1038/nCHeMBIO.557
DIScUSSIoN
Here we describe a drug profiling methodology based on a sensi-
tive Y3H system. The performance of our Y3H system is primarily 
based on (i) the engineering of the yeast reporter strain and (ii) the 
choice of SNAP-tag for anchoring and displaying the derivatized 
drug inside yeast cells. Together, these measures allowed the gene-
ration of hits of high confidence; for example, all 173 hits isolated 
from the selections with methotrexate encoded hDHFR. From a 
practical standpoint, Y3H screenings offer a number of features 
that make them attractive for drug profiling. First, cDNA libraries 
from various tissues and species validated for the Y2H system can 
be employed and are commercially available. The screening results 
of dasatinib demonstrated the importance of testing multiple cDNA 
libraries, as this increased the number of target proteins  uncovered. 
We also anticipate that, as in the case of Y2H experiments, 
array-based screens could further increase the performance of the 
system13. A second attractive feature of Y3H screenings is that the 
same pretransformed yeast stocks can be used repeatedly for screen-
ings with different drugs, thus greatly simplifying the screening 
procedure. Finally, Y3H screenings do not require advanced instru-
mentation or special expertise. Disadvantages of the Y3H approach 
include the necessity to derivatize the drug of interest, its restric-
tion to membrane-permeable drugs and its restriction to proteins or 
domains that can be functionally expressed in the nucleus of yeast. 
The wide range of applications of the SNAP-tag technology enables 
additional uses for the BG drug derivatives. In particular, coupling 
of the drug derivatives to GST-SNAP enabled the use of the same 
drug derivatives for affinity purifications. This opens up the excit-
ing possibility of running Y3H screenings and chemical proteomics 
experiments in parallel.
In this study, we identified new binding partners for approved 
drugs. We found the first nonkinase target of the EGFR inhibitor 
erlotinib, ORP7. We also characterized off-targets of the popular 
HMG-CoA reductase inhibitor atorvastatin, suggesting that ator-
vastatin has an affinity for certain isoprenoid-binding proteins 
such as PDE6D. The most intriguing finding of this work is that 
the popular anti-inflammatory drug sulfasalazine and its meta-
bolites, sulfapyridine and mesalamine, are inhibitors of the enzyme 
SPR. Despite its long use and clinical importance in the  treatment 
of IBDs and rheumatoid arthritis, its mechanism of action is not 
understood. The inhibition of SPR by sulfasalazine and its meta-
bolites and a resulting decrease in BH4 biosynthesis provides an 
attractive explanation for some of the drug’s properties and suggests 
new and improved therapies. Genetic or chemical inhibition of the 
biosynthesis of the cofactor BH4 is known to affect the activity of 
NOS34,35,47. Increased activity of NOS has been associated with IBDs, 
and chemical inhibition of NOS has been shown to reduce inflam-
mation in acute experimental colitis39. Inhibition of SPR by sulfasala-
zine and its metabolites should therefore affect BH4  levels, leading 
to reduced NOS activity in the gastrointestinal tract,  providing a 
potential explanation for the efficacy of sulfasalazine in the treat-
ment of IBDs. Increased NOS activity is also observed in rheuma-
toid arthritis36, and inhibition of BH4 biosynthesis by sulfasalazine 
and its metabolites should result in an attenuation of that activity.
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Figure 5 | Analysis of the interaction of sulfasalazine with SPR. (a) Yeast cells coexpressing lexA-SnAP and GAl4AD-SPR are dependent on the 
presence of BG-sulfasalazine for growth on selective medium. (b) A sulfasalazine affinity matrix was prepared by binding of GST-SnAP to glutathione 
beads and subsequent reaction with BG-sulfasalazine. A lysate of u2oS cells expressing v5-SPR was incubated with the matrix. Bound protein was 
analyzed by immunoblotting with HRP-labeled anti-v5 antibody. (c) A lysate of HeK 293 cells was incubated with the sulfasalazine matrix. Bound 
protein was analyzed by immunoblotting with anti-SPR primary antibody and HRP-labeled secondary antibody. For competition experiments, cell lysates 
were preincubated with sulfasalazine (10 μM (+) or 100 μM (++)). Full blots are available in Supplementary Figure 14c. (d) The inhibitory activities of 
sulfasalazine, sulfapyridine, N-acetylsulfapyridine (N-Ac sulfapyridine), mesalamine and N-acetylserotonin (N-Ac serotonin) against human SPR were 
measured in a spectrophotometric assay. The activity of SPR was normalized between 0 (no enzyme) and 1 (no inhibitor). The relative activity of SPR was 
fitted to the concentration of inhibitor using a dose-response equation with variable slope. Data represent mean values ± s.d. of triplicates. (e) The effect 
of SPR inhibitors on cellular total biopterin levels was analyzed in rat pheochromatocytoma PC12 cells using an assay based on liquid chromatography and 
fluorescence detection. Cells were incubated with SPR inhibitors in medium supplemented with 10 μM sepiapterin. Rat and human SPR showed similar 
IC50s toward sulfasalazine and its metabolites (Supplementary Fig. 13). Data represent mean values ± s.d. of at least triplicates.
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A specific inhibition of BH4 biosynthesis also suggests new 
thera peutic applications for this drug. For example, cancer patients 
with a reduced-function haplotype in BH4 biosynthesis show a 
delayed need for opioid therapy48. Consequently, sulfasalazine 
might be effective in delaying pain in cancer patients. The observa-
tion that sulfasalazine blocks the development of tactile allodynia 
in diabetic rats supports the hypothesis that sulfasalazine could 
be used for alleviation of chronic pain49. Additionally, it has been 
shown that N-acetylserotonin, a less potent inhibitor of SPR than 
sulfasalazine and sulfapyridine in vitro and in cell culture, attenu-
ated inflammatory pain in a rat model through inhibition of BH4 
biosynthesis47. Finally, our discovery that BH4 biosynthesis is inhib-
ited by sulfasalazine might permit the suppression of some of its side 
effects by adjunct therapy, as it is possible that harmful side effects, 
such as anorexia, headache, nausea and vomiting may be caused 
by a change in the concentration of neurotransmitters dependent 
on BH4 for their biosynthesis. In consequence, these side effects 
might be attenuated by adjunct therapy with molecules (such as 
neurotransmitters, their biosynthetic precursors or reuptake inhibi-
tors), which would restore a correct balance of neurotransmit-
ters. The fact that patients with deficiency in SPR are responsive 
to treatment with L-dopa supports this hypothesis50. Undoubtedly, 
the discovery that sulfasalazine and its metabolites are inhibitors of 
BH4 biosynthesis opens up a variety of exciting possibilities for this 
70-year-old drug.
mETHoDS
Yeast strain and cDNA libraries. The reporter yeast strain 1A2 was derived 
from NMY51 (Dualsystems Biotech). 1A2 genotype: MATa his3-Δ200 trp1-901 
leu2-3,112 ade2 LYS2::(lexAop)4-HIS3 ura3::(lexAop)8-lacZ (lexAop)8-ADE2 
yor1::(lexAop)8-URA3 GAL4 Δpdr5::loxP Δsnq2::loxP. A description of the strain 
modification is available in the Supplementary Methods. Human cDNA libraries 
were from Clontech and from Dualsystems Biotech.
Preparation of library yeast stocks. SNAP-tag was cloned into vector pLexA-N 
(Dualsystems Biotech, Supplementary Methods). SNAP-tag was prepared in 
the lab of K. Johnsson. All details about the sequence and origin of SNAP-tag are 
given in the Supplementary Methods. The yeast strain 1A2 was transformed with 
the SNAP-tag bait plasmid according to standard procedures. The strain 1A2 + 
bait plasmid was then transformed with human cDNA libraries achieving at least 
5 × 106 transformants per library (Supplementary Methods). The transformed 
cells were homogeneously spread (4-mm diameter glass beads) on 50 large plates 
(150-mm diameter) containing complete minimal medium minus leucine  
tryptophan (CM–LW). After 3 d at 30 °C, the yeast cells were resuspended in  
1× TE (10 mM Tris-Cl, 1 mM EDTA, pH 7.5) and pooled. The yeast cells were 
washed twice with one pellet volume 1× TE and resuspended in one pellet volume 
freezing solution (65% (v/v) glycerol, 100 mM MgSO4, 25 mM Tris-Cl pH 8). The 
yeast stocks were aliquoted and stored at −80 °C.
Negative preselection step. The viability of the pretransformed yeast stocks was 
determined by plating serial dilutions on CM–LW (in general, 4 × 108–7 × 108  
colony forming units (c.f.u.) per ml). A volume of yeast stock containing 6 × 107 
viable yeast cells was diluted in 1× TE and spread homogeneously onto 20 large 
plates (150-mm diameter) containing CM–LW + 0.25 g l−1 5-FOA (20 mg l−1 uracil, 
1% (w/v) agarose). After 3 d at 30 °C, the yeast cells were resuspended in 1× TE 
and pooled. The yeast cells were washed twice with one pellet volume 1× TE,  
resuspended in one pellet volume freezing solution and stored at −80 °C.
Y3H selections. Each Y3H selection (one drug derivative versus one cDNA library) 
was performed on one large plate (150-mm diameter) containing complete minimal 
medium minus histidine leucine tryptophan (CM–HLW) + 2.5 mM 3-amino-1,2, 
4-triazole (3-AT) + 10–20 μM BG drug derivative (diluted from a 10–20 mM stock 
in DMSO) + 1% (w/v) agarose, pH 6.5. Then, 5–25 μl thawed yeast stock (1 × 
108–7 × 108 c.f.u. per ml) was diluted in 1× TE and homogeneously spread on the 
selection plates. After 10 d at 30 °C, all colonies larger than 1 mm in diameter were 
picked and resuspended in 250 μl 1× TE in 96-well plates. Using a metal 96-prong 
replicator, the resuspended colonies were transferred onto CM–LW. After 4 d at  
30 °C, the arrayed colonies were transferred back to 250 μl 1× TE in 96-well  
plates. We spotted 2 μl of the resuspended yeast cells each on CM–LW,  
CM–HLW + 1 mM 3-AT + 0.1% (v/v) DMSO + 1.5% (w/v) agarose, pH 6.5,  
and CM–HLW + 1 mM 3-AT + 5–10 μM drug derivative + 1.5% (w/v) agarose,  
pH 6.5 using an eight-channel pipette. Colonies showing drug derivative  
growth dependence were grown in 0.85 ml CM–LW in 96-well deep well plates. 
After growth until saturation, the yeast cultures were centrifuged at 1,000g  
for 10 min. The yeast pellets were resuspended in 200 μl zymolyase solution  
(1.2 M sorbitol, 100 mM sodium phosphate pH 7.4, zymolyase 20T 2 mg ml−1) and 
incubated at 37 °C for 90 min with shaking. Plasmid DNA was then isolated with a 
commercial kit according to the manufacturer’s instructions (NucleoSpin M-96 Plus 
Plasmid, Macherey-Nagel). The cDNA inserts were amplified by PCR and analyzed by 
sequencing (Macrogen). The cDNA identity was determined by BLAST analysis.
SNAP-tag–based GST pulldown. The open reading frames of the proteins of 
interest were inserted in vector pcDNA3.1/nV5-DEST (Invitrogen) for N-terminal 
V5-tagged protein expression by Gateway recombination from relevant entry 
clones. U2OS cells (maintained in DMEM supplemented with 10% (v/v) FBS) were 
transfected with the resulting constructs using Lipofectamine 2000 (Invitrogen) 
in 3.5-cm dishes. After transient expression for 48 h, the cells were lysed on ice for 
10 min in buffer A (50 mM Tris-Cl pH 7.9, 150 mM NaCl, 5 mM EDTA, 1% (v/v) 
Triton X-100, 50 mM NaF, 1 mM Na3VO4, protease inhibitor cocktail (Complete 
Mini, Roche)). The lysate was cleared by centrifugation at 16,000g for 10 min at  
4 °C and used as input sample in subsequent pulldown experiments. For the  
preparation of the pulldown matrix, 20 μl of 20% (v/v) glutathione Sepharose 4B 
slurry (GE Healthcare) in buffer B (50 mM Tris-Cl pH 7.9, 0.5 M NaCl) was mixed 
with an Escherichia coli lysate containing bead-saturating amounts of recombinant 
GST-SNAP for 30 min at 4 °C. After washing twice with 200 μl buffer A and  
resuspension in 50 μl buffer A, the immobilized GST-SNAP was labeled with the 
drug derivative by addition of 0.5 μl of 1 mM drug derivative in DMSO. After 30 min 
at room temperature, the beads were washed twice with 200 μl buffer A and  
then incubated with 50 μl mammalian protein extract for 1–3 h at 4 °C. For  
competition experiments, 0.5 μl of 1 or 10 mM underivatized drug in DMSO  
was added to the extract and incubated for 30 min on ice. After washing three 
times with 200 μl buffer A, bound protein was eluted in 20 μl 50 mM Tris-Cl pH 
7.9 + 10 mM reduced glutathione. Eluted proteins were resolved by SDS-PAGE  
and transferred to a PVDF membrane. Immunoblotting was performed  
using anti-V5-HRP (Invitrogen), ECL Plus Western Blotting Detection Reagents  
(GE Healthcare) and a Kodak Image Station 440CF. In the blots, the input lane 
corresponds to 5–10% of the protein used in the pulldown assay. For experiments 
using endogenous protein levels, a lysate of HEK 293 cells (10–15 μg μl−1) was 
prepared in the same way as for U2OS cells. Immunoblotting was performed using 
a rabbit anti-SPR antibody (Abcam ab96027) or a mouse anti-PDE6D antibody 
(Abcam ab55563) and an appropriate HRP-labeled secondary antibody. 
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